Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The most severe variant seen in the peroxisome biogenesis disorders that is characterized by neuronal migration defects in the brain, dysmorphic craniofacial features, profound hypotonia, neonatal seizures, and liver dysfunction.
No HPO annotations are available for this condition.
Age of onset: at birth, adulthood.
The characteristic clinical features of classic PEX7-RCDP are skeletal abnormalities, cataracts, growth restriction, and intellectual disability. Life expectancy is shortened; most children do not survive beyond the first decade of life and a proportion die in the neonatal period. Of 35 affected children older than age one month, 90% survived to age one year, 55% to age five years, and approximately 20% to age 12 years . In a separate review of 66 individuals with PEX7-RCDP, 80% survived to age five years, 45% to age 12 years, and 35% to adulthood . Most deaths in these cohorts were secondary to respiratory complications. Some infants may die in the neonatal period; this number is not known.
PEX7-related rhizomelic chondrodysplasia punctata (PEX7-RCDP) should be suspected based on the individual's age and the severity of clinical and skeletal/radiographic findings.
Classic (Severe) PEX7-RCDP (the majority of affected individuals)
Neonatal period
Congenital cataracts
No approved treatments are currently available for Zellweger spectrum disorders. The disease remains an area of unmet medical need.
No clinical practice guidelines for PEX7-related rhizomelic chondrodysplasia punctata (PEX7-RCDP) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with PEX7-RCDP, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. PEX7-Related Rhizomelic Chondrodysplasia Punctata: Recommended Surveillance
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
45 publications have been identified in PubMed for Zellweger spectrum disorders. Research spans Case Report / Case Series (33%), Basic Science / Preclinical (31%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 15 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:02 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Zellweger spectrum disorders
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
Rhizomelia (proximal shortening of the long bones)
Chondrodysplasia punctata (CDP). Punctate calcifications observed in radiographs in the epiphyseal cartilage at the knee, hip, elbow, and shoulder that can be more extensive, involving the hyoid bone, larynx, costochondral junctions, and vertebrae. Metaphyseal abnormalities may be present .
Radiolucent coronal clefts of the vertebral bodies on lateral spine radiographs that represent unossified cartilage (See .)
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
Genetic disorders in the differential diagnosis of PEX7-related rhizomelic chondrodysplasia punctata (PEX7-RCDP) are listed in .
Table 2.
PEX7-Related Rhizomelic Chondrodysplasia Punctata: Genes of Interest in the Differential Diagnosis
Gene(s) | Disorder | MOI | Features of Disorder
Overlapping w/PEX7-RCDP | Distinguishing from PEX7-RCDP
AGPS | AGPS-related rhizomelic CDP1 (OMIM 600121) | AR | Clinically identical | None
ARSL (ARSE) | X-linked chondrodysplasia punctata 1 (ARSE-related XL CDP; arylsulfatase E deficiency) | XL | CDP | • Absence of rhizomelia cataracts
Males have nasomaxillary hypoplasia brachytelephalangy.
Females are not affected.
Normal plasmalogen levels
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
Biomarker and diagnostic research for Zellweger spectrum disorders has been reported in the published literature.
Table 3.
PEX7-Related Rhizomelic Chondrodysplasia Punctata: Recommended Evaluations Following Initial Diagnosis
Organ/Concern | Evaluation | Comment
| Measure erythrocyte plasmalogen levels if not already performed. | To help differentiate between classic (severe) nonclassic (mild) PEX7-RCDP, to set appropriate growth, medical, developmental expectations
| Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:
Gross motor fine motor skills
Contractures assoc pain, mobility, activities of daily living, need for adaptive devices
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
Skeletal survey to incl AP/lateral spine, AP bilateral lower extremities in 1 view, AP bilateral upper extremities, flexion/extension cervical spine | Document extent of skeletal dysplasia chondrodysplasia punctata.
| MRI of entire spine (incl flexion extension views of cervical spine for cervical stenosis) sho...
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
Anecdotal reports of natural plasmalogen precursor (alkylglycerol) supplementation in a few individuals with classic PEX7-RCDP have not indicated dramatic clinical benefit; however, alkylglycerol supplementation in humans has not yet been studied in a systematic fashion. A synthetic plasmalogen precursor was recently trialed in healthy adults for safety, tolerability, and pharmacokinetics . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
2 trials found
Evaluation |
|---|
Frequency |
|---|
accumulation | In children w/nonclassic (mild) PEX7-RCDP: measure phytanic acid levels.1 | Annually Musculoskeletal |
Cardiovascular | Cardiac exam, echocardiogram, EKG as needed | Per treating cardiologist |
Skin | Assess for eczema, ichthyosis, other rashes. | At each visit |
Kidney stones | Low threshold to assess for kidney stones w/urine imaging studies | As needed |
Source: GeneReviews — "PEX7-Related Rhizomelic Chondrodysplasia Punctata"
Estimated prevalence: Unknown (Unknown prevalence).
Laboratory research |
14 |
31% |
Testing and diagnosis research | 4 | 9% |
Clinical study results | 4 | 9% |
Research summaries | 3 | 7% |
New treatment approaches | 3 | 7% |
Disease patterns and progression | 2 | 4% |
Bodnya C (2026). [PMID: 41756896](https://pubmed.ncbi.nlm.nih.gov/41756896/). *bioRxiv : the preprint server for biology*. [Case Report / Case Series]
Sadek AA (2026). [PMID: 42151956](https://pubmed.ncbi.nlm.nih.gov/42151956/). *BMC Pediatr*. [Case Report / Case Series]
Bhattacharjee D (2026). [PMID: 42182360](https://pubmed.ncbi.nlm.nih.gov/42182360/). *bioRxiv*. [Basic Science / Preclinical]
Sidorina A (2026). [PMID: 41429203](https://pubmed.ncbi.nlm.nih.gov/41429203/). *Journal of lipid research*. [Case Report / Case Series]
Bülow MH (2026). [PMID: 41623420](https://pubmed.ncbi.nlm.nih.gov/41623420/). *Contact (Thousand Oaks (Ventura County, Calif.))*. [Case Report / Case Series]
Morita T (2026). [PMID: 42091476](https://pubmed.ncbi.nlm.nih.gov/42091476/). *Nihon Yakurigaku Zasshi*. [Gene Therapy / Novel Therapeutics]
Eberhart T (2026). [PMID: 41815956](https://pubmed.ncbi.nlm.nih.gov/41815956/). *Frontiers in molecular neuroscience*. [Basic Science / Preclinical]
Sohn EJ (2026). [PMID: 41810923](https://pubmed.ncbi.nlm.nih.gov/41810923/). *Analytical cellular pathology (Amsterdam)*. [Gene Therapy / Novel Therapeutics]
Theunis M (2026). [PMID: 41126390](https://pubmed.ncbi.nlm.nih.gov/41126390/). *Ophthalmic genetics*. [Case Report / Case Series]
Su J (2026). [PMID: 41495707](https://pubmed.ncbi.nlm.nih.gov/41495707/). *BMC pediatrics*. [Case Report / Case Series]
AI-curated news mentioning Zellweger spectrum disorders
Updated Apr 14, 2026
Research demonstrates that in vivo base editing effectively rescues liver pathophysiology and peroxisome dysfunction in a mouse model of Zellweger spectrum disorder. This breakthrough could pave the way for novel therapeutic strategies targeting this rare genetic condition.